ANNX
Annexon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.01
+17.60%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 1.9M | 3.7M | 3.5M | — | — |
| Gross Profit | (1.9M) | (3.7M) | (3.5M) | — | — |
| Operating Expenses | |||||
| R&D Expense | 174.7M | 184.7M | 119.4M | 113.8M | 112.5M |
| SG&A Expense | 36.4M | 31.7M | 34.6M | 28.0M | 30.9M |
| General & Admin Expense | 36.4M | 31.7M | 34.6M | 28.0M | 30.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (2.5M) | (3.7M) | (3.5M) | 1.9M | 2.2M |
| Total Operating Expenses | 208.7M | 212.7M | 150.6M | 143.7M | 145.6M |
| Cost and Expenses | 210.6M | 216.4M | 154.1M | 143.7M | 145.6M |
| Operating Income (EBIT) | (210.6M) | (216.4M) | (154.1M) | (143.7M) | (145.6M) |
| Non-Operating | |||||
| Interest Income | (3.7M) | 9.7M | 15.9M | 9.5M | 3.7M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | (3.7M) | 9.7M | 15.9M | 9.5M | 3.7M |
| Other Non-Op Income/Expense | 7.9M | 9.7M | 15.9M | 9.5M | 3.7M |
| Non-Operating Income (excl Interest) | (7.9M) | (9.7M) | (15.9M) | (9.5M) | (3.7M) |
| EBT (Pre-Tax Income) | (202.7M) | (206.7M) | (138.2M) | (134.2M) | (141.9M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (202.7M) | (206.7M) | (138.2M) | (134.2M) | (141.9M) |
| Earnings from Cont. Ops | (202.7M) | (206.7M) | (138.2M) | (134.2M) | (141.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (200.8M) | (206.7M) | (138.2M) | (134.2M) | (141.9M) |
| Per Share | |||||
| Basic EPS | ($1.16) | ($1.34) | ($1.01) | ($1.77) | ($2.60) |
| Diluted EPS | ($1.16) | ($1.34) | ($1.01) | ($1.77) | ($2.60) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 201.0M | 155.1M | 137.4M | 75.7M | 54.7M |
| Diluted Shares Outstanding | 201.0M | 155.1M | 137.4M | 75.7M | 54.7M |
| Profitability Metrics | |||||
| EBITDA | (200.5M) | (204.5M) | (136.1M) | (132.1M) | (139.8M) |
| D&A | 2.2M | 2.2M | 2.1M | 2.1M | 2.1M |
| EBIT | (202.7M) | (206.7M) | (138.2M) | (134.2M) | (141.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026